{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:25:58Z","timestamp":1792164358470,"version":"4.4.0"},"reference-count":50,"publisher":"The Endocrine Society","issue":"8","license":[{"start":{"date-parts":[[2018,7,9]],"date-time":"2018-07-09T00:00:00Z","timestamp":1531094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,8,1]]},"DOI":"10.1210\/js.2018-00118","type":"journal-article","created":{"date-parts":[[2018,7,9]],"date-time":"2018-07-09T14:00:43Z","timestamp":1531144843000},"page":"922-932","source":"Crossref","is-referenced-by-count":96,"title":["Osteoanabolic Agents for Osteoporosis"],"prefix":"10.1210","volume":"2","author":[{"given":"Andrea V","family":"Haas","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Diabetes, and Hypertension, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meryl S","family":"LeBoff","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, and Hypertension, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2018,7,9]]},"reference":[{"issue":"6","key":"2019041122040704600_B1","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1359\/jbmr.070315","article-title":"Residual lifetime risk of fractures in women and men","volume":"22","author":"Nguyen","year":"2007","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2019041122040704600_B2","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/jbmr.2393","article-title":"Risk of subsequent fractures and mortality in elderly women and men with fragility fractures with and without osteoporotic bone density: the Dubbo Osteoporosis Epidemiology Study","volume":"30","author":"Bliuc","year":"2015","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2019041122040704600_B3","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/ageing\/afu123","article-title":"Admission for osteoporotic pelvic fractures and predictors of length of hospital stay, mortality and loss of independence","volume":"44","author":"Marrinan","year":"2015","journal-title":"Age Ageing"},{"issue":"9","key":"2019041122040704600_B4","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: mechanism of action and role in clinical practice","volume":"83","author":"Drake","year":"2008","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"2019041122040704600_B5","first-page":"690","article-title":"Anabolic actions of parathyroid hormone on bone","volume":"14","author":"Dempster","year":"1993","journal-title":"Endocr Rev"},{"issue":"19","key":"2019041122040704600_B6","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"issue":"7","key":"2019041122040704600_B7","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial","volume":"316","author":"Miller","year":"2016","journal-title":"JAMA"},{"issue":"15","key":"2019041122040704600_B8","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"2019041122040704600_B9","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1210\/en.2015-1726","article-title":"Binding selectivity of abaloparatide for PTH-type-1-receptor conformations and effects on downstream signaling","volume":"157","author":"Hattersley","year":"2016","journal-title":"Endocrinology"},{"issue":"9","key":"2019041122040704600_B10","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1210\/jc.2012-2142","article-title":"Parathyroid hormone-related protein: an update","volume":"97","author":"Wysolmerski","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2019041122040704600_B11","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1002\/jbmr.5650111004","article-title":"PTH-related protein is released into the mother\u2019s bloodstream during lactation: evidence for beneficial effects on maternal calcium-phosphate metabolism","volume":"11","author":"Lippuner","year":"1996","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2019041122040704600_B12","first-page":"e1300","article-title":"Profile of abaloparatide and its potential in the treatment of postmenopausal osteoporosis","volume":"9","author":"Tella","year":"2017","journal-title":"Cureus"},{"issue":"5","key":"2019041122040704600_B13","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00223-016-0171-1","article-title":"Six weeks of daily abaloparatide treatment increased vertebral and femoral bone mineral density, microarchitecture and strength in ovariectomized osteopenic rats","volume":"99","author":"Bahar","year":"2016","journal-title":"Calcif Tissue Int"},{"issue":"11","key":"2019041122040704600_B14","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1002\/art.24879","article-title":"Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial","volume":"60","author":"Saag","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2019041122040704600_B15","unstructured":"Food and Drug Administration. TYMLOS (abaloparatide) injection. Available at: www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208743lbl.pdf. Accessed 23 January 2018."},{"key":"2019041122040704600_B16","unstructured":"Eli Lilly and Company. FORTEO teriparatide (rDNA origin) injection. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/021318s015lbl.pdf. Accessed 23 January 2018."},{"key":"2019041122040704600_B17","unstructured":"Institute for Clinical and Economic Review. Anabolic Therapies for Osteoporosis in Postmenopausal Women: Effectiveness and Value. Boston, MA: ICER; 2017."},{"issue":"4","key":"2019041122040704600_B18","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1080\/01926230490462138","article-title":"Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose","volume":"32","author":"Vahle","year":"2004","journal-title":"Toxicol Pathol"},{"issue":"7","key":"2019041122040704600_B19","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1080\/01926230601072301","article-title":"Defining a noncarcinogenic dose of recombinant human parathyroid hormone 1-84 in a 2-year study in Fischer 344 rats","volume":"34","author":"Jolette","year":"2006","journal-title":"Toxicol Pathol"},{"issue":"6","key":"2019041122040704600_B20","first-page":"2127","article-title":"Sequential parathyroid hormone\/alendronate therapy for osteoporosis--robbing Peter to pay Paul","volume":"85","author":"Horwitz","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2019041122040704600_B21","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1359\/jbmr.2003.18.1.9","article-title":"The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis","volume":"18","author":"Orwoll","year":"2003","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2019041122040704600_B22","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1210\/jc.2014-3718","article-title":"Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis","volume":"100","author":"Leder","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2019041122040704600_B23","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1086\/318811","article-title":"Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein","volume":"68","author":"Brunkow","year":"2001","journal-title":"Am J Hum Genet"},{"issue":"16","key":"2019041122040704600_B24","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"2019041122040704600_B25","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/MOL.0000000000000445","article-title":"Wnt signaling in cardiovascular disease: opportunities and challenges","volume":"28","author":"Gay","year":"2017","journal-title":"Curr Opin Lipidol"},{"issue":"10102","key":"2019041122040704600_B26","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","article-title":"Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial","volume":"390","author":"Langdahl","year":"2017","journal-title":"Lancet"},{"issue":"10117","key":"2019041122040704600_B27","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","article-title":"Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial","volume":"391","author":"Kendler","year":"2018","journal-title":"Lancet"},{"issue":"4","key":"2019041122040704600_B28","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1185\/030079906X100159","article-title":"Initial experience with teriparatide in the United States","volume":"22","author":"Gold","year":"2006","journal-title":"Curr Med Res Opin"},{"issue":"13","key":"2019041122040704600_B29","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","article-title":"The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis","volume":"349","author":"Black","year":"2003","journal-title":"N Engl J Med"},{"issue":"6","key":"2019041122040704600_B30","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s00198-009-1004-0","article-title":"Of mice and men: divergent risks of teriparatide-induced osteosarcoma","volume":"21","author":"Subbiah","year":"2010","journal-title":"Osteoporos Int"},{"issue":"12","key":"2019041122040704600_B31","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1002\/jbmr.1800","article-title":"Safety of osteoanabolic therapy: a decade of experience","volume":"27","author":"Cipriani","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"13","key":"2019041122040704600_B32","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa035725","article-title":"The effects of parathyroid hormone, alendronate, or both in men with osteoporosis","volume":"349","author":"Finkelstein","year":"2003","journal-title":"N Engl J Med"},{"issue":"3","key":"2019041122040704600_B33","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/jbmr.238","article-title":"Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis","volume":"26","author":"Cosman","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2019041122040704600_B34","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","article-title":"Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation","volume":"93","author":"Lacey","year":"1998","journal-title":"Cell"},{"issue":"9886","key":"2019041122040704600_B35","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(13)60856-9","article-title":"Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial","volume":"382","author":"Tsai","year":"2013","journal-title":"Lancet"},{"issue":"4","key":"2019041122040704600_B36","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1210\/jc.2009-1703","article-title":"Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis","volume":"95","author":"Finkelstein","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2019041122040704600_B37","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1359\/jbmr.081215","article-title":"Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS)","volume":"24","author":"Eastell","year":"2009","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2019041122040704600_B38","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa050336","article-title":"One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis","volume":"353","author":"Black","year":"2005","journal-title":"N Engl J Med"},{"issue":"12","key":"2019041122040704600_B39","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1007\/s00198-004-1636-z","article-title":"The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]","volume":"15","author":"Kurland","year":"2004","journal-title":"Osteoporos Int"},{"issue":"18","key":"2019041122040704600_B40","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1001\/archinte.164.18.2024","article-title":"Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis","volume":"164","author":"Lindsay","year":"2004","journal-title":"Arch Intern Med"},{"issue":"9999","key":"2019041122040704600_B41","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial","volume":"386","author":"Leder","year":"2015","journal-title":"Lancet"},{"issue":"10","key":"2019041122040704600_B42","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1002\/jbmr.3198","article-title":"Effects of denosumab and teriparatide transitions on bone microarchitecture and estimated strength: the DATA-Switch HR-pQCT study","volume":"32","author":"Tsai","year":"2017","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2019041122040704600_B43","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.mayocp.2016.10.009","article-title":"Eighteen months of treatment with subcutaneous abaloparatide followed by 6 months of treatment with alendronate in postmenopausal women with osteoporosis: results of the ACTIVExtend Trial","volume":"92","author":"Cosman","year":"2017","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"2019041122040704600_B44","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1359\/jbmr.1999.14.6.960","article-title":"Intermittent parathyroid hormone (1-34) treatment increases callus formation and mechanical strength of healing rat fractures","volume":"14","author":"Andreassen","year":"1999","journal-title":"J Bone Miner Res"},{"key":"2019041122040704600_B45","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1097\/00003086-199909000-00033","article-title":"Parathyroid hormone enhances fracture healing. A preliminary report","volume":"366","author":"Holzer","year":"1999","journal-title":"Clin Orthop Relat Res"},{"issue":"4","key":"2019041122040704600_B46","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00223-003-0093-6","article-title":"Treatment with parathyroid hormone hPTH(1-34), hPTH(1-31), and monocyclic hPTH(1-31) enhances fracture strength and callus amount after withdrawal fracture strength and callus mechanical quality continue to increase","volume":"74","author":"Andreassen","year":"2004","journal-title":"Calcif Tissue Int"},{"issue":"4","key":"2019041122040704600_B47","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.bone.2005.02.002","article-title":"Human parathyroid hormone (1-34) accelerates the fracture healing process of woven to lamellar bone replacement and new cortical shell formation in rat femora","volume":"36","author":"Komatsubara","year":"2005","journal-title":"Bone"},{"key":"2019041122040704600_B48","first-page":"7","article-title":"Short-term effects of teriparatide versus placebo on bone biomarkers, structure, and fracture healing in women with lower-extremity stress fractures: A pilot study","volume":"5","author":"Almirol","year":"2016","journal-title":"J Clin Transl Endocrinol"},{"issue":"2","key":"2019041122040704600_B49","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1359\/jbmr.090731","article-title":"Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures","volume":"25","author":"Aspenberg","year":"2010","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2019041122040704600_B50","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3109\/17453674.2015.1073050","article-title":"PTH 1-34 (teriparatide) may not improve healing in proximal humerus fractures. A randomized, controlled study of 40 patients","volume":"87","author":"Johansson","year":"2016","journal-title":"Acta Orthop"}],"container-title":["Journal of the Endocrine Society"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jes\/article-pdf\/2\/8\/922\/25249264\/js.2018-00118.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T10:01:44Z","timestamp":1555063304000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jes\/article\/2\/8\/922\/5050933"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,9]]},"references-count":50,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,7,9]]},"published-print":{"date-parts":[[2018,8,1]]}},"URL":"https:\/\/doi.org\/10.1210\/js.2018-00118","relation":{},"ISSN":["2472-1972"],"issn-type":[{"value":"2472-1972","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,8]]},"published":{"date-parts":[[2018,7,9]]}}}